3Scan Enhances Leadership Team with the Addition of Steve England, Ph.D., as Chief Science Officer

SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- 3Scan, the 3D digital and computational pathology company, today announced the addition of Steve England, Ph.D., to their leadership team as Chief Science Officer (CSO).

Steve England joins 3Scan from AbbVie where he led a team focused on therapy development and emerging technology.  Prior to AbbVie, he led discovery teams in pharmaceutical development at global drug makers AstraZeneca and Pfizer.

"I'm very excited to be joining the hugely talented team at 3Scan," Steve England said. "I believe that the ability to rapidly generate digital 3D models of tissue using their proprietary knife-edge scanning microscopy (KESM), coupled with enhanced analytical capabilities, will completely transform how we approach tissue pathology. 3Scan is changing the face of histology from a slow, labor-intensive, analog and qualitative field, to one which is highly automated, digital and quantitative. It's a real privilege to become part of the 3Scan team and help push the company forward."

In his new role at 3Scan, Steve will be leading the Pharma Partnering and Scientific Affairs teams.  In addition, as a member of the leadership team, he will contribute to shaping the company's overall strategic objectives.

"I am thrilled Steve has agreed to bring all of his education and expertise to 3Scan," said Todd Huffman, 3Scan Founder and CEO.  "He will not only add new perspective to how 3Scan's technology can revolutionize therapy development, but his wealth of experience will help take us from the talented team we are today to the transformational organization we want to be."

About 3Scan:   3Scan is a biotech startup in San Francisco that digitizes whole tissue samples through a technique that combines automation, machine learning and artificial intelligence.  The process was invented to revolutionize histology in support of translational medical research, pharmaceutical development and the biotech industry.

This novel approach captures high resolution images of complete tissue samples, through serial sectioning and simultaneous high-resolution image capture, enabling them to compute metrics and apply mathematical models. This technique empowers scientific discovery by creating a map of the related structures of the micro-environment and producing not only detailed 3D representations, but also decision support in the emerging field of computational pathology.

Contact:
Terri Hnatyszyn
VP, Marketing & Communications
(415) 656-8927
[email protected]

SOURCE 3Scan

Related Links

http://www.3scan.com